Top Page
Bluejay Diagnostics
(NASDAQ:BJDX)
Bluejay Diagnostics (BJDX) vs. SPDR S&P 500 ETF (SPY)
Bluejay Diagnostics Business Overview & Revenue Model
Bluejay Diagnostics Financial Statement Overview
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 249.04K | 0.00 |
| Gross Profit | -170.68K | -199.10K | -780.96K | 48.91K | -145.72K |
| EBITDA | -6.78M | -6.70M | -9.17M | -9.01M | -3.08M |
| Net Income | -6.85M | -7.72M | -9.95M | -9.30M | -3.73M |
Balance Sheet | |||||
| Total Assets | 7.12M | 6.66M | 4.87M | 13.52M | 21.02M |
| Cash, Cash Equivalents and Short-Term Investments | 5.16M | 4.30M | 2.21M | 10.11M | 19.05M |
| Total Debt | 120.21K | 222.25K | 352.98K | 492.62K | 0.00 |
| Total Liabilities | 1.14M | 927.92K | 1.97M | 1.98M | 637.16K |
| Stockholders Equity | 5.98M | 5.73M | 2.89M | 11.54M | 20.38M |
Cash Flow | |||||
| Free Cash Flow | -6.23M | -8.13M | -9.02M | -8.94M | -4.39M |
| Operating Cash Flow | -6.05M | -7.82M | -8.31M | -7.74M | -4.37M |
| Investing Cash Flow | -173.74K | -306.78K | -704.17K | -1.20M | -23.95K |
| Financing Cash Flow | 7.09M | 10.22M | 1.11M | 8.07K | 22.53M |
Bluejay Diagnostics Technical Analysis
Bluejay Diagnostics Risk Analysis
Bluejay Diagnostics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $2.91M | -0.28 | -191.39% | ― | ― | 76.53% | |
45 Neutral | $2.35M | -0.37 | -202.20% | ― | -49.63% | 82.22% | |
42 Neutral | $1.90M | -0.18 | -145.52% | ― | ― | 97.70% | |
41 Neutral | $648.65K | -0.05 | -2268.26% | ― | -12.39% | 44.61% | |
37 Underperform | $419.00 | -0.95 | ― | ― | ― | ― |
Bluejay Diagnostics Corporate Events
On March 14, 2024, Bluejay Diagnostics, Inc. entered into a securities purchase agreement with several board members and executives, including its president and CEO, to sell 62,500 shares of common stock at $2.00 per share in a private placement. The transaction, which closed on March 17, 2026 and raised $125,000 in gross proceeds, was conducted under exemptions from Securities Act registration, involved only accredited investors, and did not include registration rights, underscoring insider support for the company while resulting in a modest equity dilution for existing shareholders.
The most recent analyst rating on (BJDX) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Bluejay Diagnostics stock, see the BJDX Stock Forecast page.
On March 13, 2026, Bluejay Diagnostics responded to investor NorthStrive Fund II LP, which had proposed that the company consider acquiring a Phase-1-ready therapeutic program targeting refractory chronic cough to expand its clinical pipeline. Management emphasized that its primary focus remains on progressing the Symphony diagnostic platform, completing the SYMON II study, and managing cash resources to support long-term shareholder value.
The board and management said they will evaluate the suggested acquisition with input from clinical and regulatory advisors to determine whether it is complementary and accretive to the existing platform. They requested additional due diligence materials from NorthStrive and the unnamed counterparty, while stressing that any decision will be guided by fiduciary duties under Delaware law and the interests of current stockholders.
The most recent analyst rating on (BJDX) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Bluejay Diagnostics stock, see the BJDX Stock Forecast page.
On March 12, 2026, Bluejay Diagnostics announced that an abstract on its Symphony IL-6 Test was accepted for presentation at the 2026 Society of Academic Emergency Medicine Annual Meeting, to be held May 18–21 in Atlanta. The work will share data from SYMON-I, a multicenter pilot study examining how IL-6 levels in emergency department sepsis patients correlate with organ dysfunction measured by SOFA scores over the first three days of hospitalization.
Investigators reported that SYMON-I findings suggest emergency department IL-6 levels may be associated with subsequent organ dysfunction in sepsis and septic shock, adding to evidence that IL-6 could serve as an early biomarker in critically ill patients. Bluejay highlighted that SYMON-II, its pivotal validation study, is underway and is intended to underpin a future 510(k) submission, signaling progress toward potential FDA clearance and reinforcing the strategic importance of Symphony IL-6 within sepsis diagnostics.
The most recent analyst rating on (BJDX) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Bluejay Diagnostics stock, see the BJDX Stock Forecast page.
On February 20, 2026, Bluejay Diagnostics announced that all prefunded warrants issued in its October 2025 private placement had been fully exercised as of February 19, 2026, leaving no prefunded warrants of any class outstanding. Following these exercises, the company reported approximately 972,000 shares of common stock outstanding and disclosed that it still has cash-exercisable warrants for about 1.5 million shares, all with exercise prices of $7.00 or more per share, a development that clarifies its capitalization and potential future equity inflows for investors.
The company also highlighted that several recent Schedule 13G filings do not reflect the 1-for-4 reverse stock split completed on January 29, 2026, which means reported beneficial ownership stakes may appear overstated on a pre-split basis. Bluejay urged investors to account for this discrepancy when interpreting such filings, underscoring the importance of adjusted share counts in assessing ownership levels and market float following its capital structure changes.
The most recent analyst rating on (BJDX) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Bluejay Diagnostics stock, see the BJDX Stock Forecast page.
On February 17, 2026, Bluejay Diagnostics reported significant progress in its SYMON II multicenter IL-6 monitoring study for sepsis, having enrolled 545 patients toward a 750-patient target under approved IRB protocols. Management said the growing, diverse dataset should strengthen its regulatory case and reduce clinical execution risk as the program moves from enrollment to data analysis and regulatory engagement.
The company also detailed advances in manufacturing readiness, including completion of cartridge characterization for U.S. commercial production and antibody production sufficient for over 10 million test cartridges. Ongoing work on cartridge fabrication, validation, and material substitutions, alongside a parallel, no–single point of failure technology transfer strategy, positions Bluejay in early 2026 with reduced execution risk and greater focus on commercialization preparedness.
The most recent analyst rating on (BJDX) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Bluejay Diagnostics stock, see the BJDX Stock Forecast page.
On June 18, 2025, stockholders of Bluejay Diagnostics approved an amendment to the company’s charter to permit a reverse stock split at ratios between 1-for-2 and 1-for-20, and on January 27, 2026 the board selected a 1-for-4 ratio, filing a certificate of amendment in Delaware to implement the move. The 1-for-4 reverse stock split took effect at 12:01 a.m. Eastern Time on January 29, 2026, after which Bluejay’s common stock began trading on Nasdaq on a post-split basis under the unchanged ticker “BJDX” but with a new CUSIP, consolidating every four outstanding shares into one and cutting the share count from about 2,834,133 to roughly 708,533, with prefunded warrant shares and all equity awards and warrants adjusted proportionately. The reverse split, which leaves par value and voting rights intact and treats all stockholders uniformly, is operationally significant because it sharply reduces the number of shares outstanding while preserving ownership percentages, and it streamlines the capital structure for investors and warrant holders, who will see automatic adjustments in book-entry and street-name accounts and receive cash in lieu of fractional shares.
The most recent analyst rating on (BJDX) stock is a Hold with a $0.87 price target. To see the full list of analyst forecasts on Bluejay Diagnostics stock, see the BJDX Stock Forecast page.
On December 29, 2025, Bluejay Diagnostics announced it had completed commercial-scale production of both polyclonal and monoclonal antibodies targeting interleukin-6 (IL-6), a key biomarker for inflammatory and critical-care applications, with both antibody types meeting internal performance criteria for use in Symphony cartridge manufacturing. Internal testing showed acceptable binding, specificity and signal performance for the monoclonal detection antibodies, and the company now estimates its IL-6 antibody inventory could support production of more than nine million Symphony cartridges while also having the capability to produce additional antibodies, marking a significant operational milestone for scaling the Symphony platform even as the system remains under development and subject to further validation and regulatory review.